Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials

Circulation

Volumn 103, Issue 2, 2001, Pages 201-206

  Chew, Derek P ^a   Bhatt, Deepak L ^a   Sapp, Shelly ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Glycoproteins; Mortality; Trials

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; ORBOFIBAN; SIBRAFIBAN; XEMILOFIBAN;

ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0035895332     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.2.201     Document Type: Article

References (29)

1. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
2. Platelet hyperreactivity and prognosis in survivors of myocardial infarction
3. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial: Thrombolysis in Myocardial Infarction
4. A randomised, blinded trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE)
5. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
6. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
7. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
8. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: EXCITE Trial Investigators: Evaluation of Oral Xemilofiban in Controlling Thrombotic Events
9. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial: Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes
10. Sustained platelet GP IIb/IIIa blockade with oral orbofiban: Interim pharmacodynamic results of the SOAR study
11. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial
12. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial: Thrombolysis in Myocardial Infarction
13. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes (SYMPHONY) trial
14. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists
15. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
16. A prospective multicenter study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention: The GOLD study
17. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: Administration for complex coronary intervention
18. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators
19. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban: PRISM Study Investigators: Platelet Receptor Inhibition in Ischemic Syndrome Management
20. Troponin-I identifies patients with unstable coronary artery disease who benefit from long-term oral glycoprotein IIb/IIIa inhibition
21. 2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty
22. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abciximab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters
23. Peptide ligands can bind to distinct sites in integrin αIIbβ3 and elicit different functional responses
24. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors
25. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy
26. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation
27. RGD peptides induce apoptosis by direct caspase-3 activation
28. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
29. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators